{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T21:30:16Z","timestamp":1777498216890,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Department of Pharmacology, Faculty of Science, Mahidol University"},{"name":"Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital"},{"name":"National Doping Control Centre, Mahidol University"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.jchromb.2018.03.045","type":"journal-article","created":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T15:14:06Z","timestamp":1522336446000},"page":"89-95","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["A LC\/MS\/MS method for determination of tenofovir in human plasma and its application to toxicity monitoring"],"prefix":"10.1016","volume":"1085","author":[{"given":"Narit","family":"Wiriyakosol","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apichaya","family":"Puangpetch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weerawut","family":"Manosuthi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sasinapha","family":"Tomongkon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chonlaphat","family":"Sukasem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darawan","family":"Pinthong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2018.03.045_bb0005","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/S0149-2918(02)80058-3","article-title":"Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection","volume":"24","author":"Fung","year":"2002","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jchromb.2018.03.045_bb0010","series-title":"Basic & Clinical Pharmacology","author":"Katzung","year":"2007"},{"key":"10.1016\/j.jchromb.2018.03.045_bb0015","doi-asserted-by":"crossref","first-page":"8137","DOI":"10.1016\/j.tet.2010.08.037","article-title":"Method for phosphonatediester hydrolysis: development of a one-pot synthesis of tenofovir disoproxil fumarate from tenofovir diethyl ester","volume":"66","author":"Houghtona","year":"2010","journal-title":"Tetrahedron"},{"key":"10.1016\/j.jchromb.2018.03.045_bb0020","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2165\/00003088-200443090-00003","article-title":"Tenofovir clinical pharmacology and pharmacokinetics","volume":"43","author":"Kearney","year":"2004","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jchromb.2018.03.045_bb0025","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1128\/AAC.00251-06","article-title":"Mechanism of active renal tubular efflux of tenofovir","volume":"50","author":"Ray","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jchromb.2018.03.045_bb0030","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1086\/655681","article-title":"Systematic review and meta-analysis, renal safety of tenofovir disoproxil fumarate in HIV-infected patients","volume":"51","author":"Cooper","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jchromb.2018.03.045_bb0035","first-page":"179","article-title":"Proximal tubular renal dysfunction or damage in HIV-infected patients","volume":"14","author":"del Palacio1","year":"2012","journal-title":"AIDS Rev."},{"key":"10.1016\/j.jchromb.2018.03.045_bb0040","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1089\/aid.2008.0202","article-title":"Progressive renal tubular dysfunction associated with long-term use of tenofovir","volume":"25","author":"Kinai","year":"2009","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.jchromb.2018.03.045_bb0045","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1097\/QAD.0b013e328351f68f","article-title":"Association of tenofovir exposure with kidney disease risk in HIV infection","volume":"26","author":"Scherzer","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.jchromb.2018.03.045_bb0050","author":"Kidney Disease Improving Global Outcomes (KDIGO)"},{"key":"10.1016\/j.jchromb.2018.03.045_bb0055","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1093\/jac\/dku129","article-title":"ABCC2*1C and plasma tenofovir concentration are correlated with decreased glomerular filtration rate in patients receiving a tenofovir-containing antiretroviral regimen","volume":"69","author":"Manosuthi","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jchromb.2018.03.045_bb0060","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1097\/QAD.0b013e32833202e2","article-title":"Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations","volume":"24","author":"N\u00f3voa","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.jchromb.2018.03.045_bb0065","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/QAI.0b013e31827ce4ee","article-title":"Renal impairment in patients receiving a tenofovir-cART regimen: impact of tenofovir trough concentration","volume":"62","author":"Martin","year":"2013","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.jchromb.2018.03.045_bb0070","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/jac\/dkm064","article-title":"No changes in calculated creatinine clearance after tenofovir initiation among Thai patients","volume":"59","author":"Ageron","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jchromb.2018.03.045_bb0075","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1097\/QAI.0000000000000504","article-title":"No relationship between drug transporter genetic variants and tenofovir plasma concentrations or changes in glomerular filtration rate in HIV-infected adults","volume":"68","author":"Sirirungsi","year":"2015","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.jchromb.2018.03.045_bb0080","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1128\/AAC.04930-14","article-title":"Influence of ABCC2 and ABCC4 polymorphisms on tenofovir plasma concentrations in Thai HIV-infected patients","volume":"59","author":"Rungtivasuwan","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jchromb.2018.03.045_bb0085","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jchromb.2005.10.015","article-title":"Sensitive assay for determining plasma tenofovir concentrations by LC\/MS\/MS","volume":"830","author":"Delahunty","year":"2006","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jchromb.2018.03.045_bb0090","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/bmc.1125","volume":"23","author":"Nirogi","year":"2009","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jchromb.2018.03.045_bb0095","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/chromsci\/48.9.704","article-title":"Selective determination of antiretroviral agents tenofovir, emtricitabine, and lamivudine in human plasma by a LC-MS-MS method for a bioequivalence study in healthy Indian subjects","volume":"48","author":"Yadav","year":"2010","journal-title":"J. Chromatogr. Sci."},{"key":"10.1016\/j.jchromb.2018.03.045_bb0100","series-title":"LC-MS\/MS Method for the Determination of Tenofovir From Plasma, Application Note No. 20687","author":"Phipps","year":"2013"},{"key":"10.1016\/j.jchromb.2018.03.045_bb0105","series-title":"Guidance for Industry, Bioanalytical Method Validation","author":"Biopharmaceutics Coordinating Committee in the centre for Drug Evaluation and Research in cooperation with Center for Veterinary Medicine at US Food and Drug Administration","year":"2001"},{"key":"10.1016\/j.jchromb.2018.03.045_bb0110","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/chromsci\/47.2.140","article-title":"Rapid and specific liquid chromatographic tandem mass spectrometric determination of tenofovir in human plasma and its fragmentation study","volume":"47","author":"Yadav","year":"2009","journal-title":"J. Chromatogr. Sci."},{"key":"10.1016\/j.jchromb.2018.03.045_bb0115","series-title":"Minimum Criteria for Chromatographic-Mass Spectrometric Confirmation of the Identity of Analytes for Doping Control Purposes (TD2015IDCR) 1","author":"WADA Laboratory Expert Group","year":"2015"},{"key":"10.1016\/j.jchromb.2018.03.045_bb0120","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1128\/AAC.02434-12","article-title":"Tenofovir plasma concentration according to companion drugs: a cross-sectional study of HIV-positive patients with normal renal function","volume":"57","author":"Calcagno","year":"2013","journal-title":"Antimicrobial Agents and Chromatotherapy"},{"key":"10.1016\/j.jchromb.2018.03.045_bb0125","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3851\/IMP2761","article-title":"Long-term treatment with tenofovir: preveleance of kidney tubular dysfunction and its association with tenofovir plasma concentration","volume":"14","author":"Ezinga","year":"2014","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.jchromb.2018.03.045_bb0130","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jchromb.2013.05.008","article-title":"High throughtput LC-MS\/MS method for simultaneous determination of tenofovir, lamivudine and nevirapine in human plasma","volume":"931","author":"Valluru","year":"2013","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jchromb.2018.03.045_bb0135","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/bmc.2679","article-title":"A novel LC-MS\/MS method for simultaneous quantification of tenofovir and lamivudine in human plasma and its application to a pharmacokinetics study","author":"Matta","year":"2012","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jchromb.2018.03.045_bb0140","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/j.jchromb.2009.05.029","article-title":"The simultaneous assay of tenofovir and emtricitabine in plasma using LC\/MS\/MS and isotopically labeled internal standard","volume":"877","author":"Delahunty","year":"2009","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jchromb.2018.03.045_bb0145","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jpba.2008.07.022","article-title":"Liquid chromatography-tandem mass spectrometry (LC-MS\/MS) method for simultaneous determination of tenofovir and emtricitabine in human plasma and its application to a equivalence study","volume":"48","author":"Gomes","year":"2009","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2018.03.045_bb0150","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1002\/rcm.3056","article-title":"Development of a sensitive and specific liquid chromatography\/mass spectrometry method for the determination of tenofovir in human plasma","volume":"21","author":"Hood","year":"2007","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.jchromb.2018.03.045_bb0155","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1248\/bpb.30.1784","article-title":"Determination of plasma tenofovir concentration using conventional LC-MS method","volume":"30","author":"Takahashi","year":"2007","journal-title":"Biol. Pharm. Bull."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023217317828?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023217317828?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T18:24:08Z","timestamp":1534962248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023217317828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":31,"alternative-id":["S1570023217317828"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2018.03.045","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A LC\/MS\/MS method for determination of tenofovir in human plasma and its application to toxicity monitoring","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2018.03.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}